Wenyu Huang is an Endocrinology/Metabolic physician affiliated with Northwestern University. OpenAlex indexes 79 publications with 3,469 citations (h-index 24).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
676 N Saint Clair St Fl 7
Chicago, IL 606112927
Telephone
312-695-7970Provider last certified this registry record 3 Apr 2026.
Industry payments
12 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Neurocrine BioSciences, Inc.Program year202569 payments$58,733openpaymentsdata.cms.gov ↗
- RECORDATI_RARE_DISEASES_INC.Program year202549 payments$56,584openpaymentsdata.cms.gov ↗
- Chiesi USA, Inc.Program year202510 payments$12,617openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
56.7%GLP-1 receptor agonist15.8%Trulicity46%Ozempic39%Mounjaro15%Part D≥46 patientsInsulin Analog13.6%Lantus Solostar38%Humalog Kwikpen U-10016%Basaglar Kwikpen U-10013%Tresiba Flextouch U-10011%Novolog Flexpen10%Tresiba Flextouch U-2006%Toujeo Solostar4%Insulin Lispro Kwikpen U-1004%Part D<11 patients+ 8 more classes in this area
Hormonal (systemic)
21%l-Thyroxine12.9%Levothyroxine Sodium91%Synthroid9%Part D≥88 patientsThyroid Hormone Synthesis Inhibitor1.9%Methimazole100%Part D≥17 patients+ 6 more classes in this area
Cardiovascular
9.1%Statin4.3%Atorvastatin Calcium62%Rosuvastatin Calcium26%Pravastatin Sodium11%Part D<11 patientsAngiotensin receptor blocker (ARB)1.5%Losartan Potassium100%Part D<11 patients+ 5 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Osilodrostat Treatment of Cushing Syndrome in Real-World Clinical Practice: Findings From the ILLUSTRATE study
Journal of the Endocrine Society
2025 - Patient perspectives on acromegaly disease burden: insights from a community meeting
Frontiers in Endocrinology
2025 - Management of Osilodrostat Therapy in Patients With Cushing's Syndrome: A Modified Delphi Consensus Panel
Journal of the Endocrine Society
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Clyde Yancy, MD
Northwestern University
Philip Greenland, MD
Northwestern University
Peter Kahrilas, MD
Northwestern University
Philip Gorelick, MD
Northwestern University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”